Bliss GVS Pharma Limited (506197) Fair Value & Analysis

Healthcare · IN · Market cap ₹18.0B

A solid business, but screening 80% overvalued on our models.

What matters now

• The price sits above even our optimistic bull case (₹167.11). The favourable scenario is already priced in.
• Solid but not exceptional quality (57/100) and above fair value, neither a clear bargain nor a standout compounder.
• A fairly wide model range (₹80.32 to ₹167.11) leaves room in how you read the outcome.

Price vs Fair Value (5 years)

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 15, 2026.

How to read this chart

60‑month range ₹65.30 – ₹538.69 · fair‑value band ₹80.32 – ₹167.11 · the ₹519.50 price screens above the ₹104.64 fair value. Dashed = 300-day average. As of Aug 15, 2026.

Full chart & analysis →

Which stocks are undervalued right now? Check free Discover now →

Analysis

Bliss GVS Pharma Limited (506197) currently trades at ₹519.50, while our model-based Fair Value estimate is ₹104.64, implying the stock looks roughly 79.9% overvalued today. The Quality Score stands at 57/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: high).

Over the trailing twelve months, Bliss GVS Pharma Limited generated revenue of ₹5.5B at a net margin of 12.6%. Revenue declined 27.9% year over year. It earns a return on equity of 9.2%. The stock trades on a trailing P/E of 24.6 (as of Aug 15, 2026). Fundamentals as of Aug 15, 2026

Our scenario range runs from ₹80.32 (bear case) to ₹167.11 (bull case); at ₹519.50, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 6% below its 52-week high and 341% above its 52-week low, currently above its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -36% fair-value upside, at -80%, 506197 screens richer than that median.

Fair Value models

Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.

Widest divergence: Growth Earnings (₹159.15) versus Dividend Discount (₹8.06). Highest evidence: Growth DCF (80).

Key figures & financial health

Quality Score breakdown

About the company

Bliss GVS Pharma Limited develops, manufactures, and markets pharmaceutical formulations in India. The company offers pharma products, including capsules, creams/gels/ointments, dry powder for injections and oral suspensions, effervescent tablets, eye/ear drops, injections, liquid preparations, lotions, lozenges, nasal solutions, oral solids, parenterals, …

Full company description

Bliss GVS Pharma Limited develops, manufactures, and markets pharmaceutical formulations in India. The company offers pharma products, including capsules, creams/gels/ointments, dry powder for injections and oral suspensions, effervescent tablets, eye/ear drops, injections, liquid preparations, lotions, lozenges, nasal solutions, oral solids, parenterals, pessaries, sachets, soft gelatin capsules, suppositories, suspensions, syrups, tablets, topical preparations, and transdermal patches. It also provides other healthcare products, such as balms, creams, lotions, lozenges, nasal inhalers, over the counter products, petroleum jellies, powders, roll-ons, shampoos, soaps, solutions, sprays, syrups, and vaginal washes. In addition, the company offers therapeutic products consisting of anti-bacterial, anti-biotic, anti-diabetic, anti-diarrheal, anti-emetic, anti-fungal, anti-haemorrhoidal, anti-helmintic, anti-infective, anti-inflammatory, anti-malarial, anti-microbial, anti-migraine, anti-oxidant, anti-protozoal, anti-pyretic, anti-septic, anti-spasmodic, anti-ulcer, and anti-ulcerant; and analgesic, antacid, anxiolytic, appetizer, cough syrup, erectile dysfunction, haematinic, hand sanitizer, health supplement, insecticide, laryngitis, pharyngitis, laxative, lubricant, mosquito repellant, nasal decongestant, nutritional supplement, moisturizer, prickly heat powder, skin lightening lotion, vaginal contraceptive, vaginal hygiene, and vitamin supplements, as well as medicated, complexion, moisturizing, and total protection soaps. It also exports its products. Bliss GVS Pharma Limited was incorporated in 1984 and is based in Mumbai, India.

Company description, as reported by the company or data provider.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

Bliss GVS Pharma Limited reported revenue of ₹8.1B in FY2025 versus ₹5.8B in FY2021, a compound +8.8%/yr. Reported net income was ₹843M in FY2025, compounding +5.3%/yr from FY2021.

506197 screens 80% overvalued. Compare with AstraZeneca Pharma India Limited →

Peer Group

Health Care · 2250 stocks

How this stock ranks against its sector: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median. (Industry “Drug Manufacturers - Major” was too small, so the broader sector is used.)

Valuation Multiples vs Health Care median · lower = cheaper

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.

Similar stocks

10 more Drug Manufacturers - Major stocks, each showing price versus our Fair Value estimate (as of Aug 15, 2026).

Explore undervalued stocks

More undervalued Healthcare stocks →

Frequently asked questions

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.